Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial
Journal of Clinical Oncology · 20.03.2023 · 41 (9) · 1670-1683
DOI: 10.1200/jco.22.01214 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2023. Verfasst von Tianyi Wang und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children's Medical Center, S…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE We determined the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia. PATIENTS AND METHODS This phase II trial enrolled 225 evaluable patients age ≤ 20 years between September 17, 2019, and December 31, 2021. We first conducted a safety run-in stage to determine the recommended dose. After interim analysis of the first 30 patients treated (27 at the recommended dose) showing that the treatment was safe and effective, the study enrolled additional patients according to the study design. RESULTS Complete remission was achieved in 99.0% of the 194 patients with refractory leukemia or hematologic relapse, all negative for minimal residual disease. Their overall 12-month event-free survival (EFS) was 73.5% (95% CI, 67.3 to 80.3). Relapse occurred in 43 patients (24 with CD19 + /CD22 + relapse, 16 CD19 – /CD22 + , one CD19 – /CD22 – , and two unknown). Consolidative transplantation and persistent B-cell aplasia at 6 months were associated with favorable outcomes. The 12-month EFS was 85.0% (95% CI, 77.2 to 93.6) for the 78 patients treated with transplantation and 69.2% (95% CI, 60.8 to 78.8) for the 116 nontransplanted patients ( P = .03, time-dependent covariate Cox model). All 25 patients with persistent B-cell aplasia at 6 months remained in remission at 12 months. The 12-month EFS for the 20 patients with isolated testicular relapse was 95.0% (95% CI, 85.9 to 100), and for the 10 patients with isolated CNS relapse, it was 68.6% (95% CI, 44.5 to 100). Cytokine release syndrome developed in 198 (88.0%) patients, and CAR T-cell neurotoxicity in 47 (20.9%), resulting in three deaths. CONCLUSION CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with relapsed or refractory B-acute lymphoblastic leukemia, including those with isolated or combined extramedullary relapse. [Media: see text]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, China.
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
- Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Anhui, China.
- Department of Pediatrics, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Hematology/Oncology, Shanghai Children's Hospital, Shanghai, China.
ORCID-Profile: Tianyi Wang, Jiaoyang Cai, Xinyu Wan, Shaoyan Hu, Xiaoxi Lu, Wenhua Shi, Jun J Yang, Wing Leung, Jun Lu, Ching-Hon Pui
Förderung
- NCI NIH HHS
Zitieren
APA
Wang, T., Tang, Y., Cai, J., Wan, X., Hu, S., Lu, X., Xie, Z., Qiao, X., Jiang, H., Shao, J., Yang, F., Ren, H., Cao, Q., Qian, J., Zhang, J., An, K., Wang, J., Luo, C., Liang, H., …, & Pui, C. H. (2023). Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. Journal of Clinical Oncology, 41(9), 1670-1683. https://doi.org/10.1200/jco.22.01214
Vancouver
Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, et al. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. Journal of Clinical Oncology. 2023;41(9):1670-1683. doi:10.1200/jco.22.01214
BibTeX
@article{Wang2023,
author = {Wang, Tianyi and Tang, Yanjing and Cai, Jiaoyang and Wan, Xinyu and Hu, Shaoyan and Lu, Xiaoxi and Xie, Zhiwei and Qiao, Xiaohong and Jiang, Hui and Shao, Jingbo and Yang, Fan and Ren, Hong and Cao, Qing and Qian, Juan and Zhang, Jian and An, Kang and Wang, Jianmin and Luo, Chengjuan and Liang, Huanhuan and Miao, Yan and Ma, Yani and Wang, Xiang and Ding, Lixia and Song, Lili and He, Hailong and Shi, Wenhua and Xiao, Peifang and Yang, Xiaomin and Yang, Jing and Li, Wenjie and Zhu, Yiping and Wang, Ningling and Gu, Longjun and Chen, Qimin and Tang, Jingyan and Yang, Jun J and Cheng, Cheng and Leung, Wing and Chen, Jing and Lu, Jun and Li, Benshang and Pui, Ching-Hon},
title = {Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {9},
pages = {1670--1683},
doi = {10.1200/jco.22.01214}
}
EUVIMED